ALK/EML del-TECT™ Four Color

Product Description

A study discovered the existence of a fusion gene in 3%-7% of nonsmall- cell lung cancer (NSCLC), almost entirely in adenocarcinoma patients. The novel fusion comprising portions of the echinoderm microtubule-associated-protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene resulted from a small inversion within chromosome 2p, and appears to be mutually exclusive of EGFR and KRAS mutations (1,2).

Specifications

1. Soda M., et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. 2007. Nature 448:561–566.
2. Inamura K., et al. EML4–ALK fusion is linked to histological characteristics in a subset of lung cancers. 2008. J Thorac Oncol 3:13– 17.
3. Shaw AT., et al. Clinical features and outcome of patients with non– small-cell lung cancer harboring EML4-ALK. 2009. J Clin Oncol 27:4247– 4253. 4. Saski T., et al. The biology and treatment of EML4-ALK non-small cell lung cancer. 2010. Eur J Cancer 46:1773-1780.
5. Shaw AT., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. 2011. The Lancet Oncol 12:1004-1012. 6. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.